FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2074405572> ?p ?o ?g. }

• W2074405572 endingPage "2828" @default.
• W2074405572 startingPage "2822" @default.
• W2074405572 abstract "Background— The manifestations, complications, and outcomes of cardiovascular disease differ between women and men. The safety and efficacy of pharmacological reperfusion therapy in women with ST-elevation myocardial infarction are of particular interest. Methods and Results— We investigated outcomes in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment–Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 study, which randomized ST-elevation myocardial infarction patients with planned fibrinolysis to enoxaparin or unfractionated heparin. Compared with men (n=15 696), women (n=4783) were older and more likely to have hypertension and diabetes ( P <0.001). The unadjusted 30-day mortality rate for women was >2-fold higher than for men (13.2% versus 5.4%; odds ratio, 2.66; 95% CI, 2.40 to 2.96). After adjustment for age, fibrinolytic therapy, revascularization, region, and elements of the TIMI Risk Score, women had a 1.25-fold-higher 30-day risk of death (95% CI, 1.08 to 1.46) but similar risk of intracerebral hemorrhage (adjusted odds ratio, 0.81; 95% CI, 0.52 to 1.26). The 30-day rate of death or nonfatal MI in women was reduced by enoxaparin compared with unfractionated heparin in women (15.4% versus 18.3%; P =0.007). Major bleeding was more frequent in women receiving enoxaparin compared with those receiving unfractionated heparin (2.3% versus 1.4%; P =0.022) but similar among women and men receiving enoxaparin (2.3% versus 2.0%; P =0.39). The rates of death, nonfatal myocardial infarction, or nonfatal major bleeding (net clinical benefit) were lower with enoxaparin (absolute risk reduction, 2.6% in women [ P =0.02] and 1.6% in men [ P =0.001]). Conclusions— In ExTRACT-TIMI 25, women presented with a profile of higher baseline risk and increased short-term mortality. In this large, contemporary clinical trial, women had similar relative and greater absolute risk reductions than men when treated with enoxaparin compared with unfractionated heparin as adjunctive therapy with fibrinolysis." @default.
• W2074405572 created "2016-06-24" @default.
• W2074405572 creator A5019612250 @default.
• W2074405572 creator A5022267024 @default.
• W2074405572 creator A5026099249 @default.
• W2074405572 creator A5031462926 @default.
• W2074405572 creator A5058503662 @default.
• W2074405572 creator A5060339257 @default.
• W2074405572 creator A5062053709 @default.
• W2074405572 date "2007-06-05" @default.
• W2074405572 modified "2023-10-18" @default.
• W2074405572 title "Outcomes and Optimal Antithrombotic Therapy in Women Undergoing Fibrinolysis for ST-Elevation Myocardial Infarction" @default.
• W2074405572 cites W1484129406 @default.
• W2074405572 cites W1485646988 @default.
• W2074405572 cites W1539705587 @default.
• W2074405572 cites W1607047529 @default.
• W2074405572 cites W1972190172 @default.
• W2074405572 cites W1973385182 @default.
• W2074405572 cites W1973441636 @default.
• W2074405572 cites W1977178187 @default.
• W2074405572 cites W1990077170 @default.
• W2074405572 cites W2000497034 @default.
• W2074405572 cites W2016382632 @default.
• W2074405572 cites W2057361288 @default.
• W2074405572 cites W2060521891 @default.
• W2074405572 cites W2061352775 @default.
• W2074405572 cites W2064548759 @default.
• W2074405572 cites W2071393598 @default.
• W2074405572 cites W2096753232 @default.
• W2074405572 cites W2108379652 @default.
• W2074405572 cites W2119182903 @default.
• W2074405572 cites W2132770205 @default.
• W2074405572 cites W2157763459 @default.
• W2074405572 cites W2170309901 @default.
• W2074405572 cites W2170546517 @default.
• W2074405572 cites W2325814559 @default.
• W2074405572 cites W2367892943 @default.
• W2074405572 cites W4240498547 @default.
• W2074405572 cites W4298040964 @default.
• W2074405572 doi "https://doi.org/10.1161/circulationaha.106.679548" @default.
• W2074405572 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17515461" @default.
• W2074405572 hasPublicationYear "2007" @default.
• W2074405572 type Work @default.
• W2074405572 sameAs 2074405572 @default.
• W2074405572 citedByCount "49" @default.
• W2074405572 countsByYear W20744055722012 @default.
• W2074405572 countsByYear W20744055722013 @default.
• W2074405572 countsByYear W20744055722014 @default.
• W2074405572 countsByYear W20744055722015 @default.
• W2074405572 countsByYear W20744055722016 @default.
• W2074405572 countsByYear W20744055722017 @default.
• W2074405572 countsByYear W20744055722018 @default.
• W2074405572 countsByYear W20744055722019 @default.
• W2074405572 countsByYear W20744055722021 @default.
• W2074405572 countsByYear W20744055722022 @default.
• W2074405572 countsByYear W20744055722023 @default.
• W2074405572 crossrefType "journal-article" @default.
• W2074405572 hasAuthorship W2074405572A5019612250 @default.
• W2074405572 hasAuthorship W2074405572A5022267024 @default.
• W2074405572 hasAuthorship W2074405572A5026099249 @default.
• W2074405572 hasAuthorship W2074405572A5031462926 @default.
• W2074405572 hasAuthorship W2074405572A5058503662 @default.
• W2074405572 hasAuthorship W2074405572A5060339257 @default.
• W2074405572 hasAuthorship W2074405572A5062053709 @default.
• W2074405572 hasBestOaLocation W20744055721 @default.
• W2074405572 hasConcept C126322002 @default.
• W2074405572 hasConcept C156957248 @default.
• W2074405572 hasConcept C164705383 @default.
• W2074405572 hasConcept C179755657 @default.
• W2074405572 hasConcept C2776825266 @default.
• W2074405572 hasConcept C2776884760 @default.
• W2074405572 hasConcept C2777015399 @default.
• W2074405572 hasConcept C2777557582 @default.
• W2074405572 hasConcept C2777995511 @default.
• W2074405572 hasConcept C2778825682 @default.
• W2074405572 hasConcept C2779581417 @default.
• W2074405572 hasConcept C2780387585 @default.
• W2074405572 hasConcept C2909817843 @default.
• W2074405572 hasConcept C500558357 @default.
• W2074405572 hasConcept C71924100 @default.
• W2074405572 hasConceptScore W2074405572C126322002 @default.
• W2074405572 hasConceptScore W2074405572C156957248 @default.
• W2074405572 hasConceptScore W2074405572C164705383 @default.
• W2074405572 hasConceptScore W2074405572C179755657 @default.
• W2074405572 hasConceptScore W2074405572C2776825266 @default.
• W2074405572 hasConceptScore W2074405572C2776884760 @default.
• W2074405572 hasConceptScore W2074405572C2777015399 @default.
• W2074405572 hasConceptScore W2074405572C2777557582 @default.
• W2074405572 hasConceptScore W2074405572C2777995511 @default.
• W2074405572 hasConceptScore W2074405572C2778825682 @default.
• W2074405572 hasConceptScore W2074405572C2779581417 @default.
• W2074405572 hasConceptScore W2074405572C2780387585 @default.
• W2074405572 hasConceptScore W2074405572C2909817843 @default.
• W2074405572 hasConceptScore W2074405572C500558357 @default.
• W2074405572 hasConceptScore W2074405572C71924100 @default.
• W2074405572 hasIssue "22" @default.
• W2074405572 hasLocation W20744055721 @default.
• W2074405572 hasLocation W20744055722 @default.

• next